- Tirzepatide and semaglutide are both type 2 diabetes medications that can also assist people with weight loss.
- Results from a recent study suggest that tirzepatide may be more effective in helping people who have obesity or overweight lose weight than semaglutide.
- People interested in using medications for weight loss can speak with their doctors to see if they are appropriate candidates for weight loss medications.
Maintaining a healthy weight can be challenging, but it is essential to a healthy lifestyle. Certain medications can be helpful for some people who are trying to lose weight. However, weight loss medications can vary in effectiveness, and researchers are interested in finding the best choices.
A studyTrusted Source published in JAMA Internal MedicineTrusted Source compared the effectiveness of semaglutide and tirzepatide in adults who have obesity or overweight.
The researchers found that while both groups lost weight, tirzepatide was more effective than semaglutide when it came to weight loss.
This piece of research adds essential data to what experts understand about these weight loss medications and may contribute to clinical guidelines in the future.
SemaglutideTrusted Source and tirzepatideTrusted Source are both medications that assist with chronic weight management. The Food and Drug Administration (FDA) has approved versions of these medications for certain eligible individuals.
However, research on these medications is ongoing, including how they compare. Researchers of the current study wanted to compare the effectiveness of semaglutide and tirzepatide labeled for type 2 diabetes. They wanted to see which injectable medication resulted in more weight loss.
This research was a propensity-matched cohort study that included individuals with obesity or overweight who were new users of tirzepatide or semaglutide.
The researchers collected information via electronic health records and linked third-party data. They looked at the changes in body weight that participants experienced at three months, six months, and one year.
In all, researchers included 18,386 participants in the propensity score-matched cohort. Of this number, 52% percent of the group had type 2 diabetes, and the average age of participants was 52. The average follow-up time with participants was 165 days, and slightly over 50% of participants discontinued each medication. The researchers took note of gastrointestinal adverse events that occurred among participants and found that the risk was similar for both medication groups.
Overall, the study found that tirzepatide was more effective at helping participants lose weight. About 82% of participants taking tirzepatide experienced 5% or greater weight loss. In comparison, only 66.5% of participants taking semaglutide achieved this level of weight loss.
Hi my family member I want to say that this post is awesome nice written and come with approximately all significant infos I would like to peer extra posts like this
Nice blog here Also your site loads up very fast What host are you using Can I get your affiliate link to your host I wish my site loaded up as quickly as yours lol
Usually I do not read article on blogs however I would like to say that this writeup very compelled me to take a look at and do it Your writing style has been amazed me Thank you very nice article
I loved as much as you will receive carried out right here The sketch is tasteful your authored subject matter stylish nonetheless you command get got an edginess over that you wish be delivering the following unwell unquestionably come further formerly again as exactly the same nearly very often inside case you shield this hike
I just could not depart your web site prior to suggesting that I really loved the usual info an individual supply in your visitors Is gonna be back regularly to check up on new posts
Wow superb blog layout How long have you been blogging for you make blogging look easy The overall look of your site is magnificent as well as the content